Orphan Drug Development Focused on High Unmet Medical Need.
Focused on
Pediatric Rare Diseases
Enzyme Deficiency Syndromes
Rare Autoimmune and Inflammatory Disorders
Genetic Blood Disorders
Core Innovation Areas
Targeted Rare Disease Therapies
Developing mechanism-driven treatments for rare and high-burden disorders.
Clinical Development Strategy
Regulatory-aligned development pathways designed to support clinical progression and patient safety.
Molecular Research
Advancing therapies through focused biological and genetic research models.
Long-Term Outcome Improvement
Exploring sustainable treatment approaches aimed at improving quality of life and disease management.
Sickle Cell Anemia
Sickle cell anemia is a rare inherited blood disorder caused by mutations in the HBB gene, affecting normal hemoglobin production. The disease leads to rigid, sickle-shaped red blood cells that can obstruct blood flow and reduce oxygen delivery throughout the body.
All development programs remain subject to ongoing research, clinical evaluation, and regulatory review. No therapeutic claims are made outside approved indications.
Sickle Cell Development Program
Ovantic is evaluating a targeted therapeutic development program for sickle cell disease. The program remains subject to scientific diligence, regulatory strategy, development planning, clinical evaluation, and applicable regulatory authorization.
Current Development Status
Development Focus
- Safety evaluation
- Clinical efficacy assessment
- Long-term disease management potential
Current Pipeline
Candidate
Oxrexa™
Status
Phase 3
Focus Area
Sickle cell disease
Orphan Drug
Collaboration Inquiry
Research Institutions
Clinical Investigators
Regulatory Consultants
Strategic Development Partners
Rare Disease Advocacy Groups
Quick Links
Corporate HQ
Saudi Arabia Office
